552 related articles for article (PubMed ID: 33153817)
21. Clinical Outcomes of
Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
[No Abstract] [Full Text] [Related]
22. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
23. Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
Higano CS; Dizdarevic S; Logue J; Richardson T; George S; de Jong I; Tomaszewski JJ; Saad F; Miller K; Meltzer J; Sandström P; Verholen F; Tombal B; Sartor O
Cancer; 2024 Jun; 130(11):1930-1939. PubMed ID: 38340349
[TBL] [Abstract][Full Text] [Related]
24. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
25. Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer.
von Amsberg G; Zilles M; Mansour W; Gild P; Alsdorf W; Kaune M; Böckelmann L; Hauschild J; Krisp C; Rohlfing T; Saygi C; Alawi M; Zielinski A; Langebrake C; Oh-Hohenhorst SJ; Perner S; Tilki D; Schlüter H; Graefen M; Dyshlovoy SA; Bokemeyer C
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499277
[TBL] [Abstract][Full Text] [Related]
26. Re: Vicenç Ruiz de Porras, Xieng C. Wang, Luis Palomero, et al. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Eur Urol 2021;79:722-33.
Ren S; Yang B; Wang D
Eur Urol; 2021 Dec; 80(6):e151-e152. PubMed ID: 34583845
[No Abstract] [Full Text] [Related]
27. [Chemotherapy in metastatic castration resistant prostate cancer.].
Rosino A; Ballester I; Tudela J; González-Billalabeitia E
Arch Esp Urol; 2018 Sep; 71(8):676-684. PubMed ID: 30319127
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.
Hager S; Ackermann CJ; Joerger M; Gillessen S; Omlin A
Ann Oncol; 2016 Jun; 27(6):975-984. PubMed ID: 27052650
[TBL] [Abstract][Full Text] [Related]
29. First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry.
Droz JP; Efstathiou E; Yildirim A; Cabrera P; Soo Kim C; Horchani A; Heidenreich A; Rinck-Junior JA; Hitier S; Ӧzen H
Urol Oncol; 2016 May; 34(5):234.e21-9. PubMed ID: 26777260
[TBL] [Abstract][Full Text] [Related]
30. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
Cevatemre B; Bulut I; Dedeoglu B; Isiklar A; Syed H; Bayram OY; Bagci-Onder T; Acilan C
Cell Death Dis; 2024 Feb; 15(2):132. PubMed ID: 38346967
[TBL] [Abstract][Full Text] [Related]
31. Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer.
Miyake H; Hara T; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Apr; 15(2):e217-e222. PubMed ID: 27522450
[TBL] [Abstract][Full Text] [Related]
32. Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer.
Hiew K; Hart CA; Ali A; Elliott T; Ramani V; Sangar V; Lau M; Maddineni S; Brown M; Clarke N
Eur Urol Focus; 2019 Sep; 5(5):831-841. PubMed ID: 29699892
[TBL] [Abstract][Full Text] [Related]
33. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.
Regan MM; O'Donnell EK; Kelly WK; Halabi S; Berry W; Urakami S; Kikuno N; Oh WK
Ann Oncol; 2010 Feb; 21(2):312-318. PubMed ID: 19633053
[TBL] [Abstract][Full Text] [Related]
35. Taxane refractory prostate cancer.
Mathew P; Dipaola R
J Urol; 2007 Sep; 178(3 Pt 2):S36-41. PubMed ID: 17644120
[TBL] [Abstract][Full Text] [Related]
36. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
Ecstein-Fraisse E; Su Z
Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
[TBL] [Abstract][Full Text] [Related]
37. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
38. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Corn PG; Heath EI; Zurita A; Ramesh N; Xiao L; Sei E; Li-Ning-Tapia E; Tu SM; Subudhi SK; Wang J; Wang X; Efstathiou E; Thompson TC; Troncoso P; Navin N; Logothetis CJ; Aparicio AM
Lancet Oncol; 2019 Oct; 20(10):1432-1443. PubMed ID: 31515154
[TBL] [Abstract][Full Text] [Related]
39. Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
Eskra JN; Schlicht MJ; Bosland MC
Prostate; 2019 Feb; 79(2):223-233. PubMed ID: 30345530
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]